Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Efficacy and safety of HIV fusion inhibitor albuvirtide in treatment experienced patients from phase 3 TALENT study

15 Jul 2021

Coco Chong

Share

This content is sponsored. It is intended for healthcare professionals only.

A first and only long-acting injectable available as dual therapy has been proposed due to high potency of newly developed antiretrovirals (ARV). Albuvirtide (ABT) is a second-line human immunodeficiency virus (HIV)-1 fusion inhibitor that targets glycoprotein gp41 on the surface of HIV.

Efficacy-and-safety-of-HIV-fusion-inhibitor-albuvirtide-in-treatment-experienced-patients-from-phase-3-TALENT-study

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026